ArticleAlcohol, clinical & experimental research2026
Association of GLP-1 Receptor Agonist Prescriptions and Alcohol Consumption in the National Institutes of Health's All of Us Cohort.
Article in Alcohol, clinical & experimental research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
13 authors.
Funding
Abstract
backgroundGrowing evidence suggests glucagon-like peptide-1 receptor agonists (GLP-1RAs) may represent a novel potential pharmacotherapeutic tool for alcohol use disorder (AUD). The objective of this study is to examine the association between GLP-1RA prescriptions and alcohol use.
methodsThis cohort study used a cross-sectional measure of alcohol consumption and longitudinal electronic health record (EHR) data collected between 1981 and October 2023 from NIH's All of Us Research Program, a large program to recruit and collect surveys, EHR, genomic, and wearable data from a wide array of Americans. Among 15,447 participants with at least two recorded GLP-1RA prescriptions on separate days, we created three groups based on the timing of Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) responses relative to first GLP-1RA prescription. This resulted in 3650 with current GLP-1RA prescriptions, 5642 with future GLP-1RAs (primary comparison group), and 544 with previous GLP-1RAs. AUDIT-C scores were compared across these groups and to propensity-score matched comparison groups.
resultsThose with current GLP-1RA prescriptions had statistically significant but modestly lower AUDIT-C scores compared with those with future prescriptions (incidence rate ratio [IRR] = 0.95; 95% CI: 0.91-0.99; p = 0.01). Participants with a previous GLP-1RA prescription had lower AUDIT-C scores compared with those with future prescriptions, but this difference was not statistically significant. Results were similar using a matched comparison group with the current GLP-1RA group (IRR = 0.89; 95% CI: 0.85-0.93; p ≤ 0.001) and no significant difference for the previous prescription group. Analysis of individual AUDIT-C questions shows a significant association with GLP-1RA prescriptions and frequency of drinking but not drinks per occasion or binge drinking.
conclusionsThis study's findings indicate that GLP-1RAs may reduce alcohol consumption by decreasing use frequency. Experimental studies and randomized controlled trials are needed to test the mechanisms and potential efficacy of GLP-1RAs in people with AUD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.